GreenLight SPAC Presentation Deck

Summary Risk Factors Risks relating to the proposed business combination (cont'd): • The unpredictability of the spread and treatment of the SARS-CoV-2 virus and its variants could materially harm our business prospects. • Intellectual property rights including patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our competitive position or ability to bring products to market or cause us to incur liabilities. • We do not and will not seek to protect our intellectual property rights in all jurisdictions and we may not be able to adequately enforce our intellectual property rights in those jurisdictions where we do seek protection. • The anticipated size of the addressable markets for our products may not materialize. • Our projections are subject to significant assumptions and we may not achieve them and our future results could be materially different than anticipated. • A material weakness in financial controls resulted from the classification of the ENVI warrants as components of equity instead of as derivative liabilities and the ENVI warrants have been reclassified as a step to remedy the material weakness. If we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal control over financial reporting, this may result in material misstatements of our consolidated financial statements or failure to meet our periodic reporting obligations. • Our results of operations and financial condition are subject to management's accounting judgments and estimates, as well as changes in accounting policies. We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 55

View entire presentation